Literature DB >> 3019613

Crystalluria and ciprofloxacin, influence of urinary pH and hydration.

S B Thorsteinsson, T Bergan, S Oddsdottir, R Rohwedder, R Holm.   

Abstract

Ciprofloxacin is one of the newer 4-quinolones. It combines a high antibacterial activity and a broad spectrum with favourable pharmacokinetic properties. The present study was designed to detect the influence of urinary pH and fluid consumption on crystalluria. Six healthy volunteers aged 25-41 years, 3 of each sex, participated in the study. Single doses of 1,000 and 500 mg of ciprofloxacin were given orally. The urinary pH was varied by giving each subject three different diets: a regular diet, a diet supplemented by ammonium chloride to acidify urine, and a diet supplemented by sodium bicarbonate to obtain alkaline urine. The urine volume and pH were measured and microscopically examined at 37 degrees C immediately after voiding. After the very high dose of 1,000 mg ciprofloxacin the regular diet regimen led to crystalluria in only one subject. Even with this high dose, but with the acidifying regimen, no crystals were observed in any one of the volunteers. When bicarbonate was supplemented 5 to 6 volunteers presented crystals in 22 of the 36 urine samples. 21 of the crystalluric urine samples showed a pH greater than or equal to 7.3. After the usual 500-mg dose and regular diet no crystals were observed at all; only in 3 subjects who received bicarbonate supplement crystals have been seen. In the urine of two subjects crystals emerged 'ex vivo' after some hours of storage at both 37 degrees C and room temperature; these results show the importance of sediment observation at 37 degrees C immediately after voiding to differentiate between real and 'ex vivo' crystalluria. Results of different examinations permit the conclusion that the crystals contain mostly unchanged ciprofloxacin as major component and magnesium as characteristic element. Participation of the metabolite 2 in the crystal formation cannot be excluded. No significant change was observed in blood counts and blood chemistry of any subject. Urinalysis showed no modifications except the eventual presence of the typical drug-related crystals. Hematuria never occurred.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019613     DOI: 10.1159/000238444

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  25 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Drug-induced urinary calculi.

Authors:  Brian R Matlaga; Ojas D Shah; Dean G Assimos
Journal:  Rev Urol       Date:  2003

Review 3.  Tolerability of fluoroquinolone antibiotics. Past, present and future.

Authors:  P Ball; G Tillotson
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

4.  Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.

Authors:  M Nakashima; T Uematsu; K Kosuge; K Umemura; H Hakusui; M Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

5.  Acute kidney injury, agranulocytosis, drug-induced liver injury, and posterior reversible encephalopathy syndrome caused by high-dose methotrexate-possible role of low activity ABC and SLC drug transporters.

Authors:  L Bielen; I Kralj; Ela Ćurčić; M Vodanović; A Boban; N Božina
Journal:  Eur J Clin Pharmacol       Date:  2018-05-22       Impact factor: 2.953

6.  Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.

Authors:  A Allen; E Bygate; M Vousden; S Oliver; M Johnson; C Ward; A Cheon; Y S Choo; I Kim
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 7.  Fluoroquinolone-induced renal failure.

Authors:  B M Lomaestro
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

8.  Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.

Authors:  P J Morrison; T G Mant; G T Norman; J Robinson; R L Kunka
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

9.  Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.

Authors:  M Nakashima; T Uematsu; K Kosuge; H Kusajima; T Ooie; Y Masuda; R Ishida; H Uchida
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 10.  Fluoroquinolones. Adverse reactions during clinical trials and postmarketing surveillance.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1989-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.